{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:09:10Z","timestamp":1794352150002,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circular RNAs are implicated in the pathogenesis of prostate cancer (PCa). However, their functions, biogenesis and molecular mechanisms remain largely elusive. Here we aimed to investigate the role of circPHGDH in PCa. Cellular behaviors were assessed by the colony formation assay, Transwell analysis, western blotting and Seahorse assay. The underlying mechanisms were investigated using a luciferase reporter assay, RNA pull-down and real-time quantitative PCR. The lactylation of ESRP1 was examined by RNA immunoprecipitation, immunoprecipitation and western blotting. Our results revealed that circPHGDH expression was upregulated in PCa tissues and cells. Furthermore, the knockdown of circPHGDH inhibited PCa cell proliferation, migration, invasion, epithelial\u2013mesenchymal transition and glycolysis. Mechanistically, circPHGDH functioned as a sponge for miR-149, which in turn directly targeted RAP1B. The biogenesis of circPHGDH was regulated by the splicing factor ESRP1. The glycolytic product lactate stabilized ESRP1 by promoting its lactylation at the K43 site; conversely, circPHGDH knockdown suppressed ESRP1 lactylation. Moreover, the silencing of circPHGDH inhibited tumor growth and metastasis in vivo via the miR-149\/RAP1B axis, whereas circPHGDH facilitated tumor progression. In conclusion, the lactylation-modified ESRP1\/circPHGDH\/miR-149\/RAP1B axis drives the progression of PCa. These findings provide novel insights into the pathogenesis of PCa and suggest promising therapeutic targets for its treatment.<\/jats:p>","DOI":"10.1038\/s12276-026-01646-x","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:50:34Z","timestamp":1772189434000},"page":"622-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A ESRP1\/circPHGDH\/miR-149\/RAP1B positive feedback loop promotes the malignant behaviors and glycolysis of prostate cancer cell"],"prefix":"10.1038","volume":"58","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8573-0659","authenticated-orcid":false,"given":"Zhenfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"1646_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390396","volume":"43","author":"LS Graham","year":"2023","unstructured":"Graham, L. S. et al. Management of prostate cancer in older adults. Am. Soc. Clin. Oncol. Educ. Book 43, e390396 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1646_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren, O. et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur. Urol. 84, 191\u2013206 (2023).","journal-title":"Eur. Urol."},{"key":"1646_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel, H. et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat. Rev. Urol. 19, 562\u2013572 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"1646_CR4","doi-asserted-by":"crossref","unstructured":"Sekhoacha, M. et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 27, 5730 (2022).","DOI":"10.3390\/molecules27175730"},{"key":"1646_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","volume":"519","author":"Y Yamada","year":"2021","unstructured":"Yamada, Y. & Beltran, H. The treatment landscape of metastatic prostate cancer. Cancer Lett 519, 20\u201329 (2021).","journal-title":"Cancer Lett"},{"key":"1646_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","volume":"524","author":"FC Cackowski","year":"2022","unstructured":"Cackowski, F. C. & Heath, E. I. Prostate cancer dormancy and recurrence. Cancer Lett 524, 103\u2013108 (2022).","journal-title":"Cancer Lett"},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo, M. Y., Rathkopf, D. E. & Kantoff, P. Treatment of advanced prostate cancer. Annu. Rev. Med. 70, 479\u2013499 (2019).","journal-title":"Annu. Rev. Med."},{"key":"1646_CR8","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu, C. X. & Chen, L. L. Circular RNAs: characterization, cellular roles, and applications. Cell 185, 2016\u20132034 (2022).","journal-title":"Cell"},{"key":"1646_CR9","doi-asserted-by":"publisher","first-page":"671309","DOI":"10.3389\/fmolb.2021.671309","volume":"8","author":"S Khan","year":"2021","unstructured":"Khan, S., Jha, A., Panda, A. C. & Dixit, A. Cancer-associated circRNA\u2013miRNA\u2013mRNA regulatory networks: a meta-analysis. Front. Mol. Biosci. 8, 671309 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"1646_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jnr.24356","volume":"98","author":"J Zang","year":"2020","unstructured":"Zang, J., Lu, D. & Xu, A. The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function. J. Neurosci. Res. 98, 87\u201397 (2020).","journal-title":"J. Neurosci. Res."},{"key":"1646_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.trecan.2020.01.012","volume":"6","author":"J Li","year":"2020","unstructured":"Li, J., Sun, D., Pu, W., Wang, J. & Peng, Y. Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer 6, 319\u2013336 (2020).","journal-title":"Trends Cancer"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.5306\/wjco.v11.i8.563","volume":"11","author":"D Tucker","year":"2020","unstructured":"Tucker, D., Zheng, W., Zhang, D. H. & Dong, X. Circular RNA and its potential as prostate cancer biomarkers. World J. Clin. Oncol. 11, 563\u2013572 (2020).","journal-title":"World J. Clin. Oncol."},{"key":"1646_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1527","volume":"10","author":"PP Coltri","year":"2019","unstructured":"Coltri, P. P., Dos, S. M. & Da, S. G. Splicing and cancer: challenges and opportunities. Wiley Interdiscip. Rev. RNA 10, e1527 (2019).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","volume":"33","author":"CC Warzecha","year":"2009","unstructured":"Warzecha, C. C., Sato, T. K., Nabet, B., Hogenesch, J. B. & Carstens, R. P. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33, 591\u2013601 (2009).","journal-title":"Mol. Cell"},{"key":"1646_CR15","doi-asserted-by":"crossref","unstructured":"Gokmen-Polar, Y. et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. Embo Rep. 20, e46078 (2019).","DOI":"10.15252\/embr.201846078"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"110237","DOI":"10.1016\/j.cellsig.2021.110237","volume":"91","author":"Y Vadlamudi","year":"2022","unstructured":"Vadlamudi, Y. & Kang, S. C. Silencing ESRP1 expression promotes caspase-independent cell death via nuclear translocation of AIF in colon cancer cells. Cell. Signal. 91, 110237 (2022).","journal-title":"Cell. Signal."},{"key":"1646_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2018.06.034","volume":"71","author":"X Li","year":"2018","unstructured":"Li, X., Yang, L. & Chen, L. L. The biogenesis, functions, and challenges of circular RNAs. Mol. Cell 71, 428\u2013442 (2018).","journal-title":"Mol. Cell"},{"key":"1646_CR18","doi-asserted-by":"crossref","unstructured":"Chelakkot, C., Chelakkot, V. S., Shin, Y. & Song, K. Modulating Glycolysis to Improve Cancer Therapy. Int. J. Mol. Sci. 24, 2606 (2023).","DOI":"10.3390\/ijms24032606"},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/erm.2022.42","volume":"25","author":"X Lv","year":"2023","unstructured":"Lv, X., Lv, Y. & Dai, X. Lactate, histone lactylation and cancer hallmarks. Expert Rev. Mol. Med. 25, e7 (2023).","journal-title":"Expert Rev. Mol. Med."},{"key":"1646_CR20","doi-asserted-by":"publisher","first-page":"688910","DOI":"10.3389\/fimmu.2021.688910","volume":"12","author":"AN Chen","year":"2021","unstructured":"Chen, A. N. et al. Lactylation, a novel metabolic reprogramming code: current status and prospects. Front. Immunol. 12, 688910 (2021).","journal-title":"Front. Immunol."},{"key":"1646_CR21","doi-asserted-by":"publisher","first-page":"1284344","DOI":"10.3389\/fimmu.2023.1284344","volume":"14","author":"J Qu","year":"2023","unstructured":"Qu, J., Li, P. & Sun, Z. Histone lactylation regulates cancer progression by reshaping the tumor microenvironment. Front. Immunol. 14, 1284344 (2023).","journal-title":"Front. Immunol."},{"key":"1646_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01216-w","volume":"8","author":"CY Yu","year":"2017","unstructured":"Yu, C. Y. et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat. Commun. 8, 1149 (2017).","journal-title":"Nat. Commun."},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1158\/0008-5472.CAN-08-4269","volume":"69","author":"CL Bailey","year":"2009","unstructured":"Bailey, C. L., Kelly, P. & Casey, P. J. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res. 69, 4962\u20134968 (2009).","journal-title":"Cancer Res."},{"key":"1646_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70354","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang, R. et al. Important roles of PI3K\/AKT signaling pathway and relevant inhibitors in prostate cancer progression. Cancer Med. 13, e70354 (2024).","journal-title":"Cancer Med."},{"key":"1646_CR25","doi-asserted-by":"crossref","unstructured":"Shorning, B. Y., Dass, M. S., Smalley, M. J. & Pearson, H. B. The PI3K\u2013AKT\u2013mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int. J. Mol. Sci. 21, 4507 (2020).","DOI":"10.3390\/ijms21124507"},{"key":"1646_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-4939-7845-8_4","volume":"1786","author":"AF van de Merbel","year":"2018","unstructured":"van de Merbel, A. F., van der Horst, G., Buijs, J. T. & van der Pluijm, G. Protocols for migration and invasion studies in prostate cancer. Methods Mol. Biol. 1786, 67\u201379 (2018).","journal-title":"Methods Mol. Biol."},{"key":"1646_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-95693-0_6","volume":"1095","author":"V Odero-Marah","year":"2018","unstructured":"Odero-Marah, V., Hawsawi, O., Henderson, V. & Sweeney, J. Epithelial\u2013mesenchymal transition (EMT) and prostate cancer. Adv. Exp. Med. Biol. 1095, 101\u2013110 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1646_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","volume":"468","author":"Z Shen","year":"2020","unstructured":"Shen, Z., Zhou, L., Zhang, C. & Xu, J. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 468, 88\u2013101 (2020).","journal-title":"Cancer Lett."},{"key":"1646_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fcell.2020.00827","volume":"8","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Circular RNA circ-0016068 promotes the growth, migration, and invasion of prostate cancer cells by regulating the miR-330-3p\/BMI-1 Axis as a competing endogenous RNA. Front. Cell. Dev. Biol. 8, 827 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"key":"1646_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12199-5","volume":"24","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. CircPHGDH downregulation decreases papillary thyroid cancer progression through miR-122-5p\/PKM2 axis. BMC Cancer 24, 511 (2024).","journal-title":"BMC Cancer"},{"key":"1646_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2174\/0929867324666170718102738","volume":"25","author":"SH Ow","year":"2018","unstructured":"Ow, S. H., Chua, P. J. & Bay, B. H. miR-149 as a potential molecular target for cancer. Curr. Med. Chem. 25, 1046\u20131054 (2018).","journal-title":"Curr. Med. Chem."},{"key":"1646_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7150\/jca.21044","volume":"9","author":"Y He","year":"2018","unstructured":"He, Y. et al. miR-149 in human cancer: a systemic review. J. Cancer 9, 375\u2013388 (2018).","journal-title":"J. Cancer"},{"key":"1646_CR33","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2147\/CMAR.S281968","volume":"13","author":"J Ma","year":"2021","unstructured":"Ma, J., Wei, H., Li, X. & Qu, X. Hsa-miR-149-5p suppresses prostate carcinoma malignancy by suppressing RGS17. Cancer Manag. Res. 13, 2773\u20132783 (2021).","journal-title":"Cancer Manag. Res."},{"key":"1646_CR34","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/or.2016.5047","volume":"36","author":"Y Chen","year":"2016","unstructured":"Chen, Y., Zhao, J., Luo, Y., Wang, Y. & Jiang, Y. Downregulated expression of miRNA-149 promotes apoptosis in side population cells sorted from the TSU prostate cancer cell line. Oncol. Rep. 36, 2587\u20132600 (2016).","journal-title":"Oncol. Rep."},{"key":"1646_CR35","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.2147\/CMAR.S246311","volume":"12","author":"C Zhou","year":"2020","unstructured":"Zhou, C. et al. Long non-coding RNA PART1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells via miR-149-5p\/MAP2K1 axis. Cancer Manag. Res. 12, 3771\u20133782 (2020).","journal-title":"Cancer Manag. Res."},{"key":"1646_CR36","doi-asserted-by":"crossref","unstructured":"Zhao, J. et al. MicroRNA\u2011149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4\u20112 CRPC cell line. Oncol. Rep. 46, 258 (2021).","DOI":"10.3892\/or.2021.8209"},{"key":"1646_CR37","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","volume":"76","author":"AA Svoronos","year":"2016","unstructured":"Svoronos, A. A., Engelman, D. M. & Slack, F. J. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 76, 3666\u20133670 (2016).","journal-title":"Cancer Res."},{"key":"1646_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1615\/CritRevEukaryotGeneExpr.2019025997","volume":"29","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Cui, M., Song, L., Zhang, M. & Zhang, J. Function, significance, and regulation of Rap1b in malignancy. Crit. Rev. Eukaryot. Gene Expr. 29, 151\u2013160 (2019).","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"1646_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3727\/096504016X14648701447779","volume":"24","author":"Y Li","year":"2016","unstructured":"Li, Y., Liu, Y., Shi, F., Cheng, L. & She, J. Knockdown of Rap1b enhances apoptosis and autophagy in gastric cancer cells via the PI3K\/Akt\/mTOR pathway. Oncol. Res. 24, 287\u2013293 (2016).","journal-title":"Oncol. Res."},{"key":"1646_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.yexcr.2018.03.019","volume":"367","author":"Z Tang","year":"2018","unstructured":"Tang, Z. et al. Rap1b enhances the invasion and migration of hepatocellular carcinoma cells by up-regulating Twist 1. Exp. Cell Res. 367, 56\u201364 (2018).","journal-title":"Exp. Cell Res."},{"key":"1646_CR41","doi-asserted-by":"publisher","first-page":"18927","DOI":"10.1002\/jcb.29213","volume":"120","author":"P Wang","year":"2019","unstructured":"Wang, P., Gu, J., Wang, K., Shang, J. & Wang, W. miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B. J. Cell. Biochem. 120, 18927\u201318936 (2019).","journal-title":"J. Cell. Biochem."},{"key":"1646_CR42","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1080\/21655979.2021.1955559","volume":"12","author":"G Cui","year":"2021","unstructured":"Cui, G. et al. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer. Bioengineered 12, 4828\u20134840 (2021).","journal-title":"Bioengineered"},{"key":"1646_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5214806","volume":"2017","author":"M Rizzo","year":"2017","unstructured":"Rizzo, M. et al. The miRNA pull out assay as a method to validate the miR-28-5p targets identified in other tumor contexts in prostate cancer. Int. J. Genomics 2017, 5214806 (2017).","journal-title":"Int. J. Genomics"},{"key":"1646_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen, L. S. et al. The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 675\u2013691 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"1646_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41418-019-0423-5","volume":"27","author":"W Zhao","year":"2020","unstructured":"Zhao, W. et al. Splicing factor derived circular RNA circUHRF1 accelerates oral squamous cell carcinoma tumorigenesis via feedback loop. Cell Death Differ. 27, 919\u2013933 (2020).","journal-title":"Cell Death Differ."},{"key":"1646_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41420-020-00381-0","volume":"7","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. Cell Death Discov. 7, 22 (2021).","journal-title":"Cell Death Discov."},{"key":"1646_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.994","volume":"12","author":"X Pan","year":"2022","unstructured":"Pan, X. et al. Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA. Clin. Transl. Med. 12, e994 (2022).","journal-title":"Clin. Transl. Med."},{"key":"1646_CR48","doi-asserted-by":"crossref","unstructured":"Yu, S., Wang, M., Zhang, H., Guo, X. & Qin, R. Circ_0092367 inhibits EMT and gemcitabine resistance in pancreatic cancer via regulating the miR-1206\/ESRP1 axis. Genes 12, (2021).","DOI":"10.3390\/genes12111701"},{"key":"1646_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1568009620666200621153831","volume":"20","author":"Y Vadlamudi","year":"2020","unstructured":"Vadlamudi, Y., Dey, D. K. & Kang, S. C. Emerging multi-cancer regulatory role of ESRP1: orchestration of alternative splicing to control EMT. Curr. Cancer Drug Targets 20, 654\u2013665 (2020).","journal-title":"Curr. Cancer Drug Targets"},{"key":"1646_CR50","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.ijbiomac.2022.10.014","volume":"222","author":"Y Luo","year":"2022","unstructured":"Luo, Y., Yang, Z., Yu, Y. & Zhang, P. HIF1alpha lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int. J. Biol. Macromol. 222, 2225\u20132243 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"1646_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110986","volume":"39","author":"J Gu","year":"2022","unstructured":"Gu, J. et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-beta signaling in regulatory T cells. Cell Rep. 39, 110986 (2022).","journal-title":"Cell Rep."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01646-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01646-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:03:43Z","timestamp":1773839023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01646-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01646-x","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients. The animal study was approved by the Experimental Animal Welfare Ethics Committee of Beijing MDKN (code: MDKN-2025-072). All animal experiments should comply with the ARRIVE guidelines. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}